Lv2
158 积分 2024-08-20 加入
The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity
1天前
已完结
Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective
1个月前
已关闭
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
6个月前
已完结
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
6个月前
已完结
皖公网安备34019202002308
